13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001017645
Total reported value
$2.9B
$2.9B
15 檔
87.4%
According to the latest 13F quarterly dataset, General Atlantic, L.p. managed an equity portfolio of $2.9B at the end of Q1 2025, spanning 15 distinct U.S. exchange-listed positions.
In Q1 2025, General Atlantic, L.p. displayed an active expansion posture, initiating 15 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ALHC | Alignment Healthcare Inc | Stock-Other | 38.12% | — | — | |
| 2 | DLO | DLocal Limited | Stock-Other | 17.89% | -7.31% | — | |
| 3 | XPEV | XPeng Inc. | Stock-Other | 13.67% | -6.73% | — | |
| 4 | ALKT | Alkami Technology Inc | Stock-Other | 8.50% | +0.89% | — | |
| 5 | AKRO | Akero Therapeutics Inc | Stock-Other | 7.11% | — | — | |
| 6 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 4.67% | -2.50% | EXIT | |
| 7 | PHVS | Pharvaris N.V. | Stock-Other | 3.97% | -2.77% | — | |
| 8 | EWCZ | European Wax Center Inc-a | Stock-Other | 1.74% | -3.53% | EXIT | |
| 9 | RPRX | Royalty Pharma plc | Stock-Healthcare | 1.57% | — | — | |
| 10 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.26% | — | — | |
| 11 | RSKD | Riskified Ltd. | Stock-Other | 0.83% | -0.05% | — | |
| 12 | ✓ | Acelyrin Inc | Stock-Other | 0.22% | — | — | |
| 13 | ADAG | Adagene Inc-adr | Stock-Other | 0.20% | — | — | |
| 14 | 5ZZ0 | Contextlogic Inc - A | Stock-Other | 0.14% | — | — | |
| 15 | GROV | Grove Collaborative Holdings | Stock-Other | 0.11% | -0.04% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ALHC | Alignment Healthcare Inc | — | NEW | New buy |
| 2 | DLO | DLocal Limited | — | NEW | New buy |
| 3 | XPEV | XPeng Inc. | — | NEW | New buy |
| 4 | ALKT | Alkami Technology Inc | — | NEW | New buy |
| 5 | AKRO | Akero Therapeutics Inc | — | NEW | New buy |
| 6 | 260 | Centessa Pharmaceuticals-adr | — | NEW | New buy |
| 7 | PHVS | Pharvaris N.V. | — | NEW | New buy |
| 8 | EWCZ | European Wax Center Inc-a | — | NEW | New buy |
| 9 | RPRX | Royalty Pharma plc | — | NEW | New buy |
| 10 | IMCR | Immunocore Holdings Plc-adr | — | NEW | New buy |
| 11 | RSKD | Riskified Ltd. | — | NEW | New buy |
| 12 | ✓ | Acelyrin Inc | — | NEW | New buy |
| 13 | ADAG | Adagene Inc-adr | — | NEW | New buy |
| 14 | 5ZZ0 | Contextlogic Inc - A | — | NEW | New buy |
| 15 | GROV | Grove Collaborative Holdings | — | NEW | New buy |
According to official SEC Form 13F filings, General Atlantic, L.p. reported a total U.S. public equity portfolio value of $2.9B across 15 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ALHC, DLO, XPEV) accounted for 87.4% of total reported equity market value during Q1 2025.
Top New Position Initiated
ALHC
市值: $1.1B
During Q1 2025, General Atlantic, L.p.'s top holdings by market value included ALHC (38.1%)、DLO (17.9%)、XPEV (13.7%). The largest single position, ALHC, represented 38.1% of total portfolio value.
In Q1 2025, General Atlantic, L.p. made 15 total portfolio adjustments, initiating 15 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.